Moreover, BTG has a very limited indication for its theraspheres ... again IF SRX reports good results from HCC trials it can petition FDA to revoke BTG indication.
Correct. Thera has a HDE which means it can only be marketed as there is no other likewise therapy. If SRX get an FDA approval to market for HCC, the HDE can be challenged very quickly.
Radioembolization with Yttrium-90 microspheres, page-9
Add to My Watchlist
What is My Watchlist?